NRSN

NeuroSense Therapeutics Ltd

NeuroSense Granted Brazilian Patent Covering PrimeC Composition NeuroSense Granted Brazilian Patent Covering PrimeC Composition PR Newswire CAMBRIDGE, Mass., April 6, 2026 Patent Protection Through...

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding...

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update PR Newswire...

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data...

PrimeC New Data to Be Presented at AD/PD 2026 Conference PrimeC New Data to Be Presented at AD/PD 2026 Conference PR Newswire CAMBRIDGE, Mass., March 18, 2026 Dr. Christian Lunetta to Present 'From...

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity JAMA Neurology Publishes Results from PARADIGM Phase...

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference PR Newswire CAMBRIDGE...

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS NeuroSense Announces Statistically Significant 65...

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering...